Loading...
Derniers dépôts
-
Maud Voisin, Philippe de Médina, Arnaud Mallinger, Florence Dalenc, Emilie Huc-Claustre, et al.. Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114 (44), pp.E9346-E9355. ⟨10.1073/pnas.1707965114⟩. ⟨hal-02316171⟩
-
Faten Merhi, Karla Alvarez-Valadez, Jenifer Trepiana, Claire Lescoat, Alexis Groppi, et al.. Targeting CAMKK2 and SOC Channels as a Novel Therapeutic Approach for Sensitizing Acute Promyelocytic Leukemia Cells to All-Trans Retinoic Acid. Cells, 2021, 10 (12), pp.3364. ⟨10.3390/cells10123364⟩. ⟨hal-03457279⟩
-
Dorian Culié, Quentin Lisan, Charlotte Leroy, Anouchka Modesto, Renaud Schiappa, et al.. Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric study. European journal of cancer, 1970, 143, pp.168-177. ⟨10.1016/j.ejca.2020.10.034⟩. ⟨hal-03618860⟩
-
Jean-Emmanuel Kurtz, Xavier Buy, Frédéric Deschamps, Erik Sauleau, Amine Bouhamama, et al.. CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. European Journal of Cancer, 2021, 143, pp.78-87. ⟨10.1016/j.ejca.2020.10.035⟩. ⟨hal-03623642⟩
-
Sylvain Manfredi, Anthony Turpin, David Malka, Emilie Barbier, Pierre Laurent-Puig, et al.. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study. Digestive and Liver Disease, 2020, 52 (10), pp.1143-1147. ⟨10.1016/j.dld.2020.06.034⟩. ⟨hal-04548048⟩
-
Sarah Atallah, Odile Casiraghi, Nicolas Fakhry, Michel Wassef, Emmanuelle Uro-Coste, et al.. A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors. European journal of cancer, 2020, 130, pp.241-249. ⟨10.1016/j.ejca.2020.01.023⟩. ⟨hal-03599053⟩
-
Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, et al.. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩. ⟨hal-03623680⟩
-
Antonin Levy, Cécile Le Péchoux, Hitesh Mistry, Isabelle Martel-Lafay, Andrea Bezjak, et al.. Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial. Journal of Thoracic Oncology, 2019, 14 (2), pp.294-297. ⟨10.1016/j.jtho.2018.09.019⟩. ⟨hal-04508663⟩
-
Liana Hardy, Brindha Kannan, Manuel Rigon, Genevieve Benton-Hawthorn, Renato Previdelli, et al.. Canine Mammary Tumours (CMTs) exploit Mitochondrial Cholesterol for aggressive reprogramming. Biochimica et Biophysica Acta - Molecular Basis of Disease, 2024, 1871 (2), pp.167546. ⟨10.1016/j.bbadis.2024.167546⟩. ⟨hal-04805257⟩
-
Anastasiia Davletgildeeva, Aleksandra Kuznetsova, Alexander Ishchenko, Murat Saparbaev, Nikita Kuznetsov. An Insight into the Mechanism of DNA Cleavage by DNA Endonuclease from the Hyperthermophilic Archaeon Pyrococcus furiosus. International Journal of Molecular Sciences, 2024, Molecular Genetics and Genomics, 25 (16), pp.8897. ⟨10.3390/ijms25168897⟩. ⟨hal-04795724⟩
-
Florence Nguyen-Khac, Marine Baron, Romain Guièze, Pierre Feugier, Alexandra Fayault, et al.. Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study). British Journal of Haematology, 2024, 205 (2), pp.495-502. ⟨10.1111/bjh.19459⟩. ⟨hal-04796762⟩
-
C. Valenza, D. Trapani, François-Clément Bidard, J. Gligorov, J. Cortés, et al.. Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?. ESMO Open, 2024, 9 (9), ⟨10.1016/j.esmoop.2024.103701⟩. ⟨hal-04724647⟩